India and Uzbekistan have launched a structured pharmaceutical and nutraceutical trade corridor in partnership with Uzbekistan’s Ministry of Health, Nutrify Today and Pharma Eurasia, positioning Tashkent as the gateway to the $7-10 billion CIS and broader Eurasian healthcare markets. The initiative combines regulatory harmonisation, investment facilitation and supply chain integration to streamline market entry for Indian manufacturers into 12 CIS nations and Central Asian markets, where nutraceuticals alone exceed $5.8 billion annually.
Commercial activation occurs at Pharma Eurasia 2026 (Tashkent, May 20-22), serving as institutional marketplace for trade agreements, JV discussions and regulatory pathways.
Uzbekistan’s pharma parks and reforms attract FDI
Uzbekistan accelerates positioning as Eurasian hub via dedicated pharma parks (Parkent-Pharm, Andijan-Pharm), regulatory modernisation and FDI incentives, reducing import dependence from 87% to foster local production. Tashkent Pharma Park offers foreign firms manufacturing/distribution bases with government-backed infrastructure, targeting Indian strengths in generics, APIs and wellness products amid rising CIS middle-class demand.
The dual-city model—Mumbai for C-suite/policy dialogue, Tashkent for execution—bridges South Asia-Eurasia trade gaps.
Nutraceuticals lead $5.8B CIS opportunity
CIS dietary supplements market ($5.8B) grows via organised pharmacy expansion and consumer shift toward vitamins, botanicals and functional nutrition, creating immediate demand for Indian formulations. Corridor addresses tightening regulations requiring quality certification, digitising supply chains and enabling clinical collaborations.
Pharma Eurasia convenes manufacturers, regulators and distributors for matchmaking.
Strategic implications for Indian exporters
The platform supports bilateral JVs, R&D partnerships and clinical trials while Nutrify Today deploys AI-driven compliance intelligence for scalable trade. For Indian firms, Uzbekistan offers geographic centrality between India/Russia/Central Asia, reducing logistics costs to $7-10B opportunity.
